EUVIMEDEUVIMED entdecken
Open Access

Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues

Youngrong Park iD, Tetiana Korzun iD, Abraham S Moses iD, Prem Singh, Peter R Levasseur, Ananiya A Demessie iD, Kongbrailatpam Shitaljit Sharma, Terry Morgan iD, Constanze J Raitmayr, Uriel Avila, Fahad Y Sabei iD, Olena R Taratula iD und 2 weitere

Small · 2024-01 · 20 (4)

DOI: 10.1002/smll.202306270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 13.09.2023. Verfasst von Youngrong Park und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Colitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent and uncontrolled inflammation is the root cause of various debilitating diseases. Given that interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a critical modulator of inflammation, inhibition of its activity with selective drug molecules (IRAK4 inhibitors) represents a promising therapeutic strategy for inflammatory disorders. To exploit the full potential of this treatment approach, drug carriers for efficient delivery of IRAK4 inhibitors to inflamed tissues are essential. Herein, the first nanoparticle‐based platform for the targeted systemic delivery of a clinically tested IRAK4 inhibitor, PF‐06650833, with limited aqueous solubility (57 µg mL −1 ) is presented. The developed nanocarriers increase the intrinsic aqueous dispersibility of this IRAK4 inhibitor by 40 times. A targeting peptide on the surface of nanocarriers significantly enhances their accumulation after intravenous injection in inflamed tissues of mice with induced paw edema and ulcerative colitis when compared to non‐targeted counterparts. The delivered IRAK4 inhibitor markedly abates inflammation and dramatically suppresses paw edema, mitigates colitis symptoms, and reduces proinflammatory cytokine levels in the affected tissues. Importantly, repeated injections of IRAK4 inhibitor‐loaded nanocarriers have no acute toxic effect on major organs of mice. Therefore, the developed nanocarriers have the potential to significantly improve the therapeutic efficacy of IRAK4 inhibitors for different inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesColitisMiceAnimalsCytokinesInflammationEdema

Stichwörter der Autor:innen

IRAK4 inhibitorVCAM1 targetinginflammationpolymeric nanoparticlessystemic delivery

Substanzen

Interleukin-1 Receptor-Associated KinasesCytokines

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, Oregon, 97201, USA.
  • Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts, 02115, USA.
  • Papé Family Pediatric Research Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code L481, Portland, Oregon, 97239, USA.
  • Department of Pathology and Laboratory Medicine, School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon, 97239, USA.
  • Department of Pharmaceutics, College of Pharmacy, Jazan University, Al Maarefah Rd, Jazan, 88723, Kingdom of Saudi Arabia.

ORCID-Profile: Youngrong Park, Tetiana Korzun, Abraham S Moses, Ananiya A Demessie, Terry Morgan, Fahad Y Sabei, Olena R Taratula, Oleh Taratula

Förderung

  • NICHD NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Park, Y., Korzun, T., Moses, A. S., Singh, P., Levasseur, P. R., Demessie, A. A., Sharma, K. S., Morgan, T., Raitmayr, C. J., Avila, U., Sabei, F. Y., Taratula, O. R., Marks, D. L., & Taratula, O. (2024). Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues. Small, 20(4). https://doi.org/10.1002/smll.202306270

Vancouver

Park Y, Korzun T, Moses AS, Singh P, Levasseur PR, Demessie AA, et al. Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues. Small. 2024;20(4). doi:10.1002/smll.202306270

BibTeX
@article{Park2024,
  author = {Park, Youngrong and Korzun, Tetiana and Moses, Abraham S and Singh, Prem and Levasseur, Peter R and Demessie, Ananiya A and Sharma, Kongbrailatpam Shitaljit and Morgan, Terry and Raitmayr, Constanze J and Avila, Uriel and Sabei, Fahad Y and Taratula, Olena R and Marks, Daniel L and Taratula, Oleh},
  title = {Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues},
  journal = {Small},
  year = {2024},
  volume = {20},
  number = {4},
  doi = {10.1002/smll.202306270}
}
Kostenlos starten →